CYTOMED THERAPEUTICS LTD (GDTC) Fundamental Analysis & Valuation

NASDAQ:GDTC • SGXZ17669631

1.06 USD
+0.01 (+0.97%)
At close: Mar 4, 2026
1.0203 USD
-0.04 (-3.75%)
After Hours: 3/4/2026, 5:15:56 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GDTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GDTC. GDTC was compared to 520 industry peers in the Biotechnology industry. The financial health of GDTC is average, but there are quite some concerns on its profitability. GDTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. GDTC Profitability Analysis

1.1 Basic Checks

  • In the past year GDTC has reported negative net income.
  • In the past year GDTC has reported a negative cash flow from operations.
  • In the past 5 years GDTC always reported negative net income.
  • In the past 5 years GDTC always reported negative operating cash flow.
GDTC Yearly Net Income VS EBIT VS OCF VS FCFGDTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

  • GDTC has a Return On Assets (-43.94%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of -51.38%, GDTC is in the better half of the industry, outperforming 64.81% of the companies in the same industry.
Industry RankSector Rank
ROA -43.94%
ROE -51.38%
ROIC N/A
ROA(3y)-39.42%
ROA(5y)-40.55%
ROE(3y)-198.44%
ROE(5y)-215.73%
ROIC(3y)N/A
ROIC(5y)N/A
GDTC Yearly ROA, ROE, ROICGDTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • GDTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GDTC Yearly Profit, Operating, Gross MarginsGDTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. GDTC Health Analysis

2.1 Basic Checks

  • GDTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GDTC remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for GDTC has been increased compared to 5 years ago.
  • Compared to 1 year ago, GDTC has a worse debt to assets ratio.
GDTC Yearly Shares OutstandingGDTC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GDTC Yearly Total Debt VS Total AssetsGDTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • GDTC has an Altman-Z score of 4.34. This indicates that GDTC is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.34, GDTC is doing good in the industry, outperforming 71.35% of the companies in the same industry.
  • GDTC has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.06, GDTC perfoms like the industry average, outperforming 40.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 4.34
ROIC/WACCN/A
WACC8.52%
GDTC Yearly LT Debt VS Equity VS FCFGDTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

  • GDTC has a Current Ratio of 5.81. This indicates that GDTC is financially healthy and has no problem in meeting its short term obligations.
  • GDTC's Current ratio of 5.81 is fine compared to the rest of the industry. GDTC outperforms 61.35% of its industry peers.
  • GDTC has a Quick Ratio of 5.81. This indicates that GDTC is financially healthy and has no problem in meeting its short term obligations.
  • GDTC's Quick ratio of 5.81 is fine compared to the rest of the industry. GDTC outperforms 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
GDTC Yearly Current Assets VS Current LiabilitesGDTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. GDTC Growth Analysis

3.1 Past

  • The earnings per share for GDTC have decreased strongly by -19.89% in the last year.
EPS 1Y (TTM)-19.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.93%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GDTC Yearly Revenue VS EstimatesGDTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 100K 200K 300K 400K 500K
GDTC Yearly EPS VS EstimatesGDTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

Find the best growth stocksShow best growing peers

0

4. GDTC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GDTC. In the last year negative earnings were reported.
  • Also next year GDTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDTC Price Earnings VS Forward Price EarningsGDTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GDTC Per share dataGDTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GDTC Dividend Analysis

5.1 Amount

  • No dividends for GDTC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GDTC Fundamentals: All Metrics, Ratios and Statistics

CYTOMED THERAPEUTICS LTD

NASDAQ:GDTC (3/4/2026, 5:15:56 PM)

After market: 1.0203 -0.04 (-3.75%)

1.06

+0.01 (+0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)04-28
Inst Owners0.2%
Inst Owner ChangeN/A
Ins Owners12.62%
Ins Owner Change0%
Market Cap12.37M
Revenue(TTM)225.40K
Net Income(TTM)-3.67M
Analysts82.86
Price TargetN/A
Short Float %5.18%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.14
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.23
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.02
BVpS0.48
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.94%
ROE -51.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.42%
ROA(5y)-40.55%
ROE(3y)-198.44%
ROE(5y)-215.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 267.85%
Cap/Sales 413.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z 4.34
F-Score3
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)193.79%
Cap/Depr(5y)170.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.15%
EPS Next Y-13.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-8.93%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-35.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.75%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMED THERAPEUTICS LTD / GDTC FAQ

Can you provide the ChartMill fundamental rating for CYTOMED THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 2 / 10 to GDTC.


What is the valuation status for GDTC stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOMED THERAPEUTICS LTD (GDTC). This can be considered as Overvalued.


How profitable is CYTOMED THERAPEUTICS LTD (GDTC) stock?

CYTOMED THERAPEUTICS LTD (GDTC) has a profitability rating of 1 / 10.


How financially healthy is CYTOMED THERAPEUTICS LTD?

The financial health rating of CYTOMED THERAPEUTICS LTD (GDTC) is 5 / 10.